Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Maves vs Nalena

Maves
Graded #91

Higher grade

vs+0.3999999999999915
Nalena
Graded #98

Lower grade

The verdict

Maves takes it — 71.6/100 to 71.2/100, but only just.

Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with… Nalena is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +9
83
74
Dose & formulationMaves +1
65
64
Clinical oversightNalena +6
76
82
Labs & monitoringNalena +1
52
53
FulfillmentNalena +2
87
89
Contract termsNalena +6
55
61
Maves · left barNalena · right bar

The numbers

MetricMavesNalena
WeighScore71.6/10071.2/100
GradeCC
Scorecard rank#91#98
Semaglutide$99/mo (starting dose, first-month rate, compounded)$149/mo (starting dose, compounded)
TirzepatideNot disclosed$149/mo (starting dose, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Maves

Graded #91 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed
Nalena

Graded #98 · C

Strengths

  • Compounded GLP-1 from $149/mo with medication included — near the floor of the compounded market
  • Transparent fee model: no hidden fees, no membership, cancel anytime
  • Money-back guarantee — uncommon among compounded telehealths
  • Clinical provider disclosed: Beluga Health, P.A. in Houston, TX
  • Women-focused positioning

Where it loses points

  • Per-dose pricing not published — only the 'starting at $149' entry price
  • No LegitScript, HIPAA, or NABP badges on public pages
  • Compounding pharmacy partners not named (only 'multiple USA certified pharmacies')
  • Houston address looks like a virtual office rather than a clinical facility
  • No brand-name GLP-1s (Wegovy, Zepbound, Ozempic, Mounjaro) — compounded only

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard